Related Experiment Videos
Chemotherapy in NSCLC: historical review
1Department of Medical Oncology, Ygeia Hospital, 2an Tsoka & Vas Sofias Aven, 11521 Athens, Greece. parkosmi@otenet.gr
Lung Cancer (Amsterdam, Netherlands)
|December 7, 2002
Summary
Platinum-based chemotherapy significantly improves survival for patients with advanced non-small cell lung cancer (NSCLC). This treatment is now the established standard for managing advanced NSCLC, offering a 10% survival benefit at one year.
Area of Science:
- Medical Oncology
- Clinical Research
- Pulmonology
Background:
- Chemotherapy's role in advanced non-small cell lung cancer (NSCLC) has evolved.
- Initially for palliative care, it's now integrated into curative-intent therapies for locoregionally-advanced NSCLC.
Observation:
- A major 1995 meta-analysis evaluated platinum-based chemotherapy efficacy.
- This analysis focused on patients with advanced NSCLC.
Findings:
- Platinum-based chemotherapy demonstrated significant effectiveness in advanced NSCLC.
- It resulted in a 10% absolute improvement in 1-year survival.
- Median survival increased by 1.5 months.
Implications:
- Platinum-based chemotherapy is recognized as the gold standard treatment for advanced NSCLC.
- These findings support its continued use and further research in NSCLC treatment protocols.